Previous 10 | Next 10 |
-- Novel cryoanalgesia treatment highly complementary to EXPAREL -- -- Corporate name change to Pacira BioSciences to reflect expanding product portfolio -- -- Conference call today at 8:30 AM ET -- PARSIPPANY, N.J. and FREMONT, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Paci...
Pacira Pharmaceuticals, Inc. (PCRX) Q4 2018 Results Earnings Conference Call February 28, 2019 08:30 AM ET Company Participants Susan Mesco - Head of Investor Relations David Stack - Chief Executive Officer and Chairman Richard Scranton - Chief Medical Officer Charles Reinha...
Pacira Pharmaceuticals ( PCRX ) Q4 results : Revenues: $95.1M (+20.2%); EXPAREL: $94.4M (+19.9%); Other product sales: $0.3M (+50.0%); Royalty revenue: $0.4M (+100.0%). More news on: Pacira Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, ...
Pacira Pharmaceuticals (NASDAQ: PCRX ): Q4 Non-GAAP EPS of $0.47 beats by $0.20 ; GAAP EPS of $0.20 beats by $0.14 . More news on: Pacira Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Increasing adoption of EXPAREL ® Across Opioid-Sparing Pain Management Protocols -- -- EXPAREL net product sales expected to be in the range of $400M to $410M in 2019 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Pac...
PARSIPPANY, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2018 financial results before the open of the U.S. markets on Thursday, February 28, 2019. Following the release,...
PARSIPPANY, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that commercial production of EXPAREL® (bupivacaine liposome injectable suspension) is now underway at a custom suite in Swindon, UK created under the company’s p...
Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda...
-- Product-specific C-code for ambulatory surgical center procedures and D-code for dental procedures to take effect January 1, 2019 -- -- Important reimbursement milestone that will expand patient access to non-opioid strategies for postsurgical pain -- PARSIPPANY, N.J., Nov...
Pacira Pharmaceuticals, Inc. (PCRX) Q3 2018 Earnings Call November 01, 2018 8:30 am ET Executives Susan Mesco - Pacira Pharmaceuticals, Inc. David M. Stack - Pacira Pharmaceuticals, Inc. Richard E. Scranton - Pacira Pharmaceuticals, Inc. Charles A. Reinhart III - Pacira Pharmac...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...